Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20664223 | 1.00 | GAA (0.44) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL35210100 | 1.00 | GAA (0.44) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL35210112 | 1.00 | GAA (0.44) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL15280630 | 1.00 | GAA (0.44) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL21919553 | 0.86 | GAA (0.42) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL21350997 | 0.85 | GAA (0.43) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL16653387 | 0.84 | HCRTR2 (0.32) | EPHX2 | |
| SCHEMBL16653213 | 0.84 | HCRTR2 (0.32) | EPHX2 | |
| SCHEMBL22796742 | 0.82 | GAA (0.46) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL29559237 | 0.82 | GAA (0.46) | GAANFKB1NFKB2RELAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2849568-B1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3430906-A1 | CRYSTALLINE FORMS OF CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9850246-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850246-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9487523-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487523-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160130273-A1 | Process for Making CGRP Receptor Antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130273-A1 | Process for Making CGRP Receptor Antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-05-12 | — | — | US | disclosed |
| US-9174989-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174989-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
| WO-2013138418-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | CALCR, CALCRL, VIPR1 | GAA 4256/4885NFKB1 1697/4885NFKB2 2251/4885 |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | CCKBR, BDKRB2, CALCR | GAA 4109/4885NFKB1 885/4885NFKB2 849/4885 |
| US-20160130273-A1 | Process for Making CGRP Receptor Antagonists | CALCR, CALCRL, VIPR1 | GAA 4310/4885NFKB1 1290/4885NFKB2 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.